SRP426633 Track Settings
 
DNA methylation alterations in prostate cancer patient derived xenograft models revealed by whole genome bisulfite sequencing [Patient Derived Xenograft]   (Human methylome studies)

This track is part of a parent called 'Human methylome studies'. To show other tracks of this parent, go to the Human methylome studies configuration page.

Maximum display mode:       Reset to defaults   

Select views (help):
CpG reads ▾       CpG methylation ▾       AMR       PMD      
Select subtracks by views and experiment:
 All views CpG reads  CpG methylation  AMR  PMD 
experiment
SRX19634831 
SRX19634832 
SRX19634833 
SRX19634834 
SRX19634835 
SRX19634836 
SRX19634837 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 SRX19634831  CpG reads  Patient Derived Xenograft / SRX19634831 (CpG reads)   schema 
hide
 SRX19634831  CpG methylation  Patient Derived Xenograft / SRX19634831 (CpG methylation)   schema 
hide
 SRX19634831  AMR  Patient Derived Xenograft / SRX19634831 (AMR)   schema 
hide
 SRX19634831  PMD  Patient Derived Xenograft / SRX19634831 (PMD)   schema 
hide
 SRX19634832  CpG methylation  Patient Derived Xenograft / SRX19634832 (CpG methylation)   schema 
hide
 SRX19634832  AMR  Patient Derived Xenograft / SRX19634832 (AMR)   schema 
hide
 SRX19634832  PMD  Patient Derived Xenograft / SRX19634832 (PMD)   schema 
hide
 SRX19634832  CpG reads  Patient Derived Xenograft / SRX19634832 (CpG reads)   schema 
hide
 SRX19634833  CpG reads  Patient Derived Xenograft / SRX19634833 (CpG reads)   schema 
hide
 SRX19634833  CpG methylation  Patient Derived Xenograft / SRX19634833 (CpG methylation)   schema 
hide
 SRX19634833  AMR  Patient Derived Xenograft / SRX19634833 (AMR)   schema 
hide
 SRX19634833  PMD  Patient Derived Xenograft / SRX19634833 (PMD)   schema 
hide
 SRX19634834  CpG reads  Patient Derived Xenograft / SRX19634834 (CpG reads)   schema 
hide
 SRX19634834  CpG methylation  Patient Derived Xenograft / SRX19634834 (CpG methylation)   schema 
hide
 SRX19634834  AMR  Patient Derived Xenograft / SRX19634834 (AMR)   schema 
hide
 SRX19634834  PMD  Patient Derived Xenograft / SRX19634834 (PMD)   schema 
hide
 SRX19634835  AMR  Patient Derived Xenograft / SRX19634835 (AMR)   schema 
hide
 SRX19634835  CpG reads  Patient Derived Xenograft / SRX19634835 (CpG reads)   schema 
hide
 SRX19634835  CpG methylation  Patient Derived Xenograft / SRX19634835 (CpG methylation)   schema 
hide
 SRX19634835  PMD  Patient Derived Xenograft / SRX19634835 (PMD)   schema 
hide
 SRX19634836  CpG reads  Patient Derived Xenograft / SRX19634836 (CpG reads)   schema 
hide
 SRX19634836  CpG methylation  Patient Derived Xenograft / SRX19634836 (CpG methylation)   schema 
hide
 SRX19634836  AMR  Patient Derived Xenograft / SRX19634836 (AMR)   schema 
hide
 SRX19634836  PMD  Patient Derived Xenograft / SRX19634836 (PMD)   schema 
hide
 SRX19634837  CpG reads  Patient Derived Xenograft / SRX19634837 (CpG reads)   schema 
hide
 SRX19634837  CpG methylation  Patient Derived Xenograft / SRX19634837 (CpG methylation)   schema 
hide
 SRX19634837  AMR  Patient Derived Xenograft / SRX19634837 (AMR)   schema 
hide
 SRX19634837  PMD  Patient Derived Xenograft / SRX19634837 (PMD)   schema 
    

Study title: DNA methylation alterations in prostate cancer patient derived xenograft models revealed by whole genome bisulfite sequencing
SRA: SRP426633
GEO: not found
Pubmed: not found

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Title
SRX19634831 Patient Derived Xenograft 0.443 22.4 106841 8504.4 1870 983.1 5261 164593.5 0.979 GSM7091438: 147 Whole Genome Bisulfite Sequencing 30X; Homo sapiens; Bisulfite-Seq
SRX19634832 Patient Derived Xenograft 0.742 20.9 86989 4916.8 2171 1059.9 2783 171729.0 0.978 GSM7091439: 173-1 Whole Genome Bisulfite Sequencing 30X; Homo sapiens; Bisulfite-Seq
SRX19634833 Patient Derived Xenograft 0.451 16.1 104552 9040.7 1438 1021.5 6773 135479.4 0.979 GSM7091440: 176 Whole Genome Bisulfite Sequencing 30X; Homo sapiens; Bisulfite-Seq
SRX19634834 Patient Derived Xenograft 0.722 16.6 91912 4599.9 2937 1100.1 2861 156819.4 0.978 GSM7091441: 208-1 Whole Genome Bisulfite Sequencing 30X; Homo sapiens; Bisulfite-Seq
SRX19634835 Patient Derived Xenograft 0.644 14.3 101087 6961.5 3178 1118.8 4148 175974.1 0.979 GSM7091442: 77 Whole Genome Bisulfite Sequencing 30X; Homo sapiens; Bisulfite-Seq
SRX19634836 Patient Derived Xenograft 0.602 20.2 149803 4881.2 3729 1158.0 5088 147018.0 0.978 GSM7091443: 78 Whole Genome Bisulfite Sequencing 30X; Homo sapiens; Bisulfite-Seq
SRX19634837 Patient Derived Xenograft 0.637 19.8 99564 7926.5 1267 969.0 4665 219111.7 0.979 GSM7091444: 93 Whole Genome Bisulfite Sequencing 30X; Homo sapiens; Bisulfite-Seq

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.